TRAF1 anticorps (AA 73-219)

N° du produit ABIN7876674

L’anticorps anti-TRAF1 Monoclonal Souris est utilisé pour la détection de TRAF1 dans des échantillons de Humain. Il a été validé pour ELISA.

Aperçu rapide pour TRAF1 anticorps (AA 73-219) (ABIN7876674)

Antigène: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TRAF1 est non-conjugé

Application: ELISA

Classe de qualité: Carrier-free

Clone: TRAF1-3299

Détail du produit anti-TRAF1 anticorps

Épitope: AA 73-219

Fonction: TRAF1 Antibody / TNFR-Associated Factor 1 (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant fragment of human TRAF1 protein (within amino acids 73-219) was used as the immunogen for the TRAF1 antibody.

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal dilution of the TRAF1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the TRAF1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur TRAF1

Antigène: TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Autre désignation: TRAF1

Sujet: This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

UniProt: Q13077

Pathways: Signalisation NF-kappaB, Apoptose, Cell-Cell Junction Organization, Asymmetric Protein Localization